April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal Bevacizumab for Retinal Arterial Macroaneurysm: A Case Series
Author Affiliations & Notes
  • Rana Mady
    Medstar Washington Hospital Center, Washington, DC
  • Frank Spellman
    Retina Group of Washington, Washington, DC
  • Marcus Colyer
    Retina Group of Washington, Washington, DC
  • Footnotes
    Commercial Relationships Rana Mady, None; Frank Spellman, None; Marcus Colyer, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 673. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rana Mady, Frank Spellman, Marcus Colyer; Intravitreal Bevacizumab for Retinal Arterial Macroaneurysm: A Case Series. Invest. Ophthalmol. Vis. Sci. 2014;55(13):673.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To further elucidate the role of anti-vascular endothelial growth factor (anti-VEGF) therapy in the treatment of macular complications following retinal arterial macroaneurysm and to potentially broaden its therapeutic role in this retinal disorder.

Methods: Retrospective case series of ten patients that were treated with intravitreal bevacizumab either alone or in conjunction with focal laser or surgery for macular complications secondary to retinal arterial macroaneurysm between the years of 2010 to 2013 at the Retina Group of Washington. Central macular thickness and visual acuity data were collected at presentation and after intravitreal injection at 1 month, 3 months and 6 months of follow-up. This research was approved by the Institutional Review Board of the MedStar Health Research Institute.

Results: A total of 10 patients were included in the study. Four patients presented with hemorrhagic complications, 3 with lipid exudates and 3 with a combination of both. Follow-up time ranged from 3 - 14 months (mean 7.6 months). Average best-corrected visual acuity (BCVA) in logMAR was 1.34 (range 0.3 - 1.6) at presentation and 0.7 (range 0 - 1.6) at final follow-up. Eight out of 10 patients had improved visual acuity at final follow-up compared to initial presentation. Clinically, macular edema completely resolved in all cases. Central macular thickness (CMT) data is available for patients #7-10. Average CMT at presentation was 443.5μm (range 331-687) and at final follow-up was 202μm (range 168-240).

Conclusions: Overall, macular edema resolved in all cases. Visual acuity improved in 8 out of the 10 cases.

Keywords: 585 macula/fovea • 748 vascular endothelial growth factor  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.